Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ATYR Stock Forecast 2026-2027
$0.44
Current Price
$43.18M
Market Cap
Buy 4
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to ATYR Price Targets
+1,490.9%
To High Target of $7.00
+581.8%
To Median Target of $3.00
+127.3%
To Low Target of $1.00
ATYR Price Momentum
0.0%
1 Week Change
-12.0%
1 Month Change
-91.5%
1 Year Change
-43.6%
Year-to-Date Change
-94.0%
From 52W High of $7.29
+11.4%
From 52W Low of $0.40
📊 TOP ANALYST CALLS
Did ATYR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if aTyr Pharma is one of their latest high-conviction picks.
Latest ATYR Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, ATYR has a neutral consensus with a median price target of $3.00 (ranging from $1.00 to $7.00). The overall analyst rating is Buy (7.3/10). Currently trading at $0.44, the median forecast implies a 581.8% upside. This outlook is supported by 4 Buy, 5 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ATYR Analyst Ratings
4
Buy
5
Hold
0
Sell
ATYR Price Target Range
Low
$1.00
Average
$3.00
High
$7.00
Current: $0.44
Latest ATYR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ATYR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 20, 2026 | Freedom Broker | Ilya Zubkov | Buy | Upgrade | $3.50 |
| Nov 7, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Sep 16, 2025 | Wells Fargo | Equal-Weight | Downgrade | $N/A | |
| Sep 16, 2025 | RBC Capital | Sector Perform | Downgrade | $N/A | |
| Sep 15, 2025 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| Sep 15, 2025 | Leerink Partners | Market Perform | Downgrade | $N/A | |
| Sep 15, 2025 | Jones Trading | Hold | Downgrade | $N/A | |
| Sep 15, 2025 | Cantor Fitzgerald | Neutral | Downgrade | $N/A | |
| Sep 15, 2025 | LUCID CAPITAL MARKETS | Neutral | Downgrade | $N/A | |
| Aug 22, 2025 | Jefferies | Buy | Maintains | $N/A | |
| Jun 20, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Jun 4, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 19, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 14, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 18, 2025 | Leerink Partners | Outperform | Initiates | $N/A | |
| Jan 6, 2025 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Dec 10, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 3, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 29, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 4, 2024 | Wells Fargo | Overweight | Initiates | $N/A |
aTyr Pharma, Inc. (ATYR) Competitors
The following stocks are similar to aTyr Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
aTyr Pharma, Inc. (ATYR) Financial Data
aTyr Pharma, Inc. has a market capitalization of $43.18M with a P/E ratio of -0.5x. The company generates $190,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -38,573.7% and return on equity of -105.6%.
Valuation Metrics
Market Cap
$43.18M
Enterprise Value
$-8,392,454
P/E Ratio
-0.5x
PEG Ratio
0.0x
Price/Sales
245.3x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-38,573.7%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+154.1%
Current Ratio
5.8x
Debt/Equity
20.3x
ROE
-105.6%
ROA
-51.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
aTyr Pharma, Inc. (ATYR) Business Model
About aTyr Pharma, Inc.
What They Do
Develops innovative therapies for fibrotic diseases.
Business Model
Atyr Pharma Inc. operates as a clinical-stage biotechnology company, generating revenue through the development of proprietary medicines utilizing its tRNA synthetase platform. The company focuses on creating first-in-class therapies for rare immune-mediated disorders, with its lead candidate, efzofitimod, currently undergoing advanced clinical trials to address significant unmet medical needs.
Additional Information
Founded in 2005 and based in San Diego, California, Atyr Pharma Inc. is advancing multiple drug candidates alongside efzofitimod, including ATYR0101 and ATYR0750, targeting fibrotic and liver disorders. The company's innovative approach aims to modulate immune responses to improve outcomes for patients with severe pulmonary and inflammatory diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
58
CEO
Dr. Sanjay S. Shukla M.D., M.S.
Country
United States
IPO Year
2015
Website
atyrpharma.comaTyr Pharma, Inc. (ATYR) Latest News & Analysis
Latest News
Quick Summary
The company will advance efzofitimod for pulmonary sarcoidosis after FDA Type C meeting, planning an IND submission in June 2026 for a Phase 3 study using FVC as the primary endpoint.
Why It Matters
The FDA's support for efzofitimod's development indicates potential for future revenue and market expansion, affecting the company's valuation and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
aTyr Pharma (NASDAQ: ATYR) will initiate a Phase III trial for efzofitimod in pulmonary sarcoidosis following FDA feedback from a Type C meeting.
Why It Matters
aTyr Pharma's new Phase III trial for efzofitimod signals potential advancement in treatment for pulmonary sarcoidosis, impacting drug prospects and future revenue.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
aTyr Pharma, Inc. (ATYR) has provided an update on FDA feedback regarding Efzofitimod for pulmonary sarcoidosis following Phase III trial results.
Why It Matters
FDA feedback on Efzofitimod's Phase III results can impact aTyr Pharma's stock price, regulatory approval timeline, and future market potential, influencing investor sentiment and decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
The company will advance efzofitimod development for pulmonary sarcoidosis, submitting an IND in June 2026 for a Phase 3 study focusing on FVC and KSQ-Lung endpoints.
Why It Matters
The company's commitment to developing efzofitimod, backed by FDA feedback, signals potential advancements in treatment for pulmonary sarcoidosis, which could impact future revenue and market positioning.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
aTyr Pharma will participate in the RBC Capital Markets Global Healthcare Conference on May 20 and the Jefferies Global Healthcare Conference on June 4, 2026, in New York.
Why It Matters
aTyr Pharma's participation in major investor conferences signals potential for increased visibility, investor interest, and opportunities for funding, crucial for its clinical development progress.
Source: GlobeNewsWire
Market Sentiment:
Neutral
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
3 months ago
Quick Summary
The company will meet with the FDA in April 2026 to discuss Phase 3 results for efzofitimod in pulmonary sarcoidosis, while Phase 2 enrollment for SSc-ILD is set to finish in H1 2026.
Why It Matters
The FDA meeting and study progress could influence efzofitimod's market potential and regulatory approval, impacting the company's valuation and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ATYR Stock
What is aTyr Pharma, Inc.'s (ATYR) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, aTyr Pharma, Inc. (ATYR) has a median price target of $3.00. The highest price target is $7.00 and the lowest is $1.00.
Is ATYR stock a good investment in 2026?
According to current analyst ratings, ATYR has 4 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.44. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ATYR stock?
Wall Street analysts predict ATYR stock could reach $3.00 in the next 12 months. This represents a 581.8% increase from the current price of $0.44. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is aTyr Pharma, Inc.'s business model?
Atyr Pharma Inc. operates as a clinical-stage biotechnology company, generating revenue through the development of proprietary medicines utilizing its tRNA synthetase platform. The company focuses on creating first-in-class therapies for rare immune-mediated disorders, with its lead candidate, efzofitimod, currently undergoing advanced clinical trials to address significant unmet medical needs.
What is the highest forecasted price for ATYR aTyr Pharma, Inc.?
The highest price target for ATYR is $7.00 from at , which represents a 1,490.9% increase from the current price of $0.44.
What is the lowest forecasted price for ATYR aTyr Pharma, Inc.?
The lowest price target for ATYR is $1.00 from at , which represents a 127.3% increase from the current price of $0.44.
What is the overall ATYR consensus from analysts for aTyr Pharma, Inc.?
The overall analyst consensus for ATYR is neutral. Out of 2 Wall Street analysts, 4 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are ATYR stock price projections?
Stock price projections, including those for aTyr Pharma, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 15, 2026 2:14 AM UTC